Virulence: Likely Increased
Antigenicity: B.1.617.2 variant is resistant to therapeutic monoclonal antibodies, natural infection’s or vaccine-induced antibodies.
Spread: Originally was discovered in India and has now spread to more than 100 countries. Variant is dominant in India & UK now (and many other Asian countries where sequence data is not widely available), but prevalence also growing fast in US, as well as many European countries.
Global Positive Samples Sequenced: 2,167,558
B.1.617.2 Sequenced: 163,338
% of Global Samples Sequenced: 7.54%
Distribution of B.1.617.2 Sequences Top 5 Countries: United Kingdom 76.0%, India 8.0%, United States of America 5.0%, Germany 2.0%, Singapore 1.0%
(Predominantly India lineage with several spike mutations.)
Updated July 2021